Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimens have relatively low efficacy rates. Clinical studies of single-target chimeric antigen receptor T cell (CAR-T cell) therapy in T lymphocytes...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Baijin, Lin, Keming, Wang, Xuemei, Chen, FeiLi, Zhou, Mo, Li, Yuzhuang, Lin, Yingtong, Qiao, Yidan, Li, Rong, Zhang, Wanying, He, Xin, Zou, Fan, Li, Linghua, Lu, Lijuan, Chen, Cancan, Li, WenYu, Zhang, Hui, Liu, Bingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427987/
https://www.ncbi.nlm.nih.gov/pubmed/37593111
http://dx.doi.org/10.1016/j.omto.2023.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427987/
https://www.ncbi.nlm.nih.gov/pubmed/37593111
http://dx.doi.org/10.1016/j.omto.2023.07.007

Ejemplares similares